Screener
Wave Life Sciences WVE Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Long-term assets: | ||
| Property and equipment, net of accumulated depreciation of $50,819 and $49,522 as of June 30, 2026 and December 31, 2025, respectively | 6,833 | 7,405 |
| Operating lease right-of-use assets | 39,498 | 12,458 |
| Restricted cash | 3,815 | 3,806 |
| Other assets | 667 | 16 |
| Total long-term assets | 50,813 | 23,685 |
| Total assets | $558,321 | $638,499 |
| Liabilities, Series A preferred shares, and shareholders’ equity |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's restricted cash?
- Wave Life Sciences (WVE) reported restricted cash of $3.82M in Q2 2026.
- How has Wave Life Sciences's restricted cash changed year-over-year?
- Wave Life Sciences's restricted cash increased by 0.8% year-over-year, from $3.78M to $3.82M.
- What is the long-term trend for Wave Life Sciences's restricted cash?
- Over 5 years (2020 to 2025), Wave Life Sciences's restricted cash has grown at a 0.8% compound annual growth rate (CAGR), from $3.65M to $3.81M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Wave Life Sciences's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude